Fiche centre
Novartis Investigative Site
Grenoble — France
Essais liés5clinical trials
VilleGrenoblelocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05126277
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06711887 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| Nilotinib followed by treatment-free | Cancer | Phase 2 | NCT01784068 | ENESTfreedom — Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients | COMPLETED |